or
Bookmark and Share
2-SUBSTITUTED-CINCHONA ALKALOIDS
   
Document Number
US Patent 3818013
Issued Date
June 18, 1974
Link
Inventors
Yardley; John P. (King of Prussia, PA)
Bright; Royal E. (Philadelphia, PA)
Map
Abstract
2'-Substituted alkaloids of the cinchona series, especially 2'-substituted quinine, quinidine, cinchonine, cinchonidine and their dihydro analogs, and their salts, are prepared by treating ar-N-oxides of the alkaloids with the corresponding organometallic reagent and, if desired, converting the free bases thus formed into pharmaceutically acceptable acid addition salts. The new compounds are pharmacologically active, especially anti-malarially and anti-arrhythmically.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
9
Comments:
no comments yet
Owner
Published
June 18, 1974
Application Number
05/230,467
Filed
February 29, 1972
US Classification
546/134  
Int'l Classification
C07D   453/04   (20060101)   C07D   453/00   (20060101)  
Examiner
Attorney/Law Firm
Parent Case
This application is a divisional of application Ser. No. 27,119, entitled "2'-Substituted-Cinchona Alkaloids," filed Apr. 9, 1970 now U.S. Pat. No. 3,643,552, which in turn is a continuation-in-part of application Ser. No. 692,277, entitled "2'-Substituted-Cinchona Alkaloids," filed Dec. 21, 1967 now abandoned.
USPTO Field of Search
260/284  
Related Patents
6617475 - Preparation of optically active .alpha.-hydroxyethers - Owned by Solvias AG (Basel,CH)

Optically active .alpha.-hydroxyethers are prepared from prochiral .alpha.-ketoethers by heterogeneous hydrogenation using platinum catalysts in the presence of a chiral nitrogen base in high chemical and optical yields, since this type of hydrogenation selectively hydrogenates only one diastereomer virtually to completion. The yields may be substantially increased by adding a solid, strong base which has a racemizing effect on the non-hydrogenatable diasteromer.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us